FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

The FDA approves a supplemental application for EMEND (fosaprepitant dimeglumine) submitted by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• EMEND (aprepitant)

Snippet

SUPPL AP for EMEND (FOSAPREPITANT DIMEGLUMINE)